EU OK To Tecentriq-Avastin Combo In NSCLC Includes EGFR-Mutant, ALK-Positive Patients

 
• By Sten Stovall
  
Cancer cells
EU Nod For Tecentriq with Avastin is based on IMpower150 study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer